Cancer and Aging
From Bench to Clinics.
1st Edition
Published on 18. January 2013
170 pages
978-3-318-02307-7 (ISBN)
Available for download
Description
Cancer is clearly an age-related disease. Recent research in both aging and cancer has demonstrated the complex interaction between the two phenomena. This affects a wide spectrum of research and practice, anywhere from basic research to health care organization. Core examples of these close associations are addressed in this book. Starting with basic research, the first chapters cover cancer development, mTOR inhibition, senescent cells altering the tumor microenvironment, and immune senescence affecting cancer vaccine response. Taking into account the multidisciplinarity of geriatric oncology, several chapters focus on geriatric and oncologic aspects in patient assessment, treatment options, nursing and exercise programs. The book is rounded off by a discussion on the impact of the metabolic syndrome illustrating the interactions between comorbidity and cancer and a chapter on frailty. This book provides the reader with insights that will hopefully foster his or her reflection in their own research and practice to further the development of this most exciting field. Given the aging of the population worldwide and the high prevalence of cancer, it is essential reading not only for oncologists and geriatricians but for all health practitioners.
More details
Other editions
Additional editions
Book
01/2013
1st Edition
S. Karger
€162.65
Article exhausted; check different version
Persons
Content
- Cover
- Front Matter
- Contents
- Preface
- Chronic Mechanistic Target of Rapamycin Inhibition: Preventing Cancer to Delay Aging, or Vice Versa?
- Abstract
- A Potential Approach?
- TOR, Aging and Cancer
- Rapamycin - A Pro- Longevity Drug That Mimics Diet Restriction - Or Does It?
- Potential Mechanisms of Rapamycin Effects on Mammalian Lifespan and Cancer
- Tumor Immune Surveillance, mTOR and Effects of Rapamycin
- The Promise of mTOR Inhibitors in the Clinic
- Final Thoughts
- Acknowledgements
- References
- Senescent Cells and Their Secretory Phenotype as Targets for Cancer Therapy
- Abstract
- Cancer and Aging
- Cellular Senescence during Aging
- Cellular Senescence and Tumor Suppression
- Cellular Senescence and Tumor Promotion and Progression
- Cellular Senescence and Cancer Therapy
- Conclusions
- References
- Cancer Vaccination at Older Age
- Abstract
- Decreased Immune Responses in Elderly
- Decreased Immune Responses in Cancer Patients
- Improvement of Cancer Vaccination at Old Age in Preclinical Models
- Concluding Remarks
- References
- Immunology of Aging and Cancer Development
- Abstract
- Does the Immune System Play a Role in the Prevention of Tumorigenesis?
- What Is Immunosenescence?
- What Could Be the Link between Immunosenescence and Cancer?
- Is There an Efficient Way to Restore the Immune Response with Aging?
- Conclusion
- Acknowledgements
- References
- Metabolic Syndrome and Cancer: From Bedside to Bench and Back
- Abstract
- From Bedside to Bench
- From Bench to Bedside
- Conclusions
- References
- Frailty: A Common Pathway in Aging and Cancer
- Abstract
- Aging, Cancer, and Frailty
- Clinical Definition of Frailty
- Frailty and Cancer
- References
- Targeting Age-Related Changes in the Biology of Acute Myeloid Leukemia: Is the Patient Seeing the Progress?
- Abstract
- What Is AML?
- Biological Specificities of AML in the Elderly
- Host- Disease Interactions in Elderly AML
- Treatment Options for Elderly Patients with AML
- How Can We Stratify Elderly Patients with AML?
- Have the Patients Seen the Progress?
- References
- Comprehensive Geriatric Assessment in Oncology
- Abstract
- Components of Geriatric Assessment
- Risk Stratification
- Are Shorter Screening Tools for Geriatric Impairment Available for Oncology Clinics?
- Moving Forward Utilizing CGA to Improve Outcomes of Older Cancer Patients
- Conclusion
- References
- Pharmacology of Aging and Cancer: How Useful Are Pharmacokinetic Tests?
- Abstract
- Background
- Should We Study Pharmacokinetics and Pharmacodynamics in Older Patients?
- Alkylating Agents
- Platinum Compounds
- Antimicrotubule Agents (Spindle Poisons) in Elderly Cancer Patients
- Purine Analogues
- Camptothecins
- Conclusion
- References
- Surgery in Older Cancer Patients - Recent Results and New Techniques: Worth the Investment?
- Abstract
- Preoperative Decision-Making
- Outcome Reports
- Postoperative Complications
- Alternatives to Surgery
- Education and Training
- References
- Organizing the Geriatrician/Oncologist Partnership: One Size Fits All? Practical Solutions
- Abstract
- The Shortage of Oncologists and Geriatricians
- Current Partnerships in Geriatrics and Oncology
- Building a Program That Integrates Geriatrics and Oncology
- Filling the Educational Gap
- Conclusion
- References
- Geriatric Oncology Nursing: Beyond Standard Care
- Abstract
- Geriatric Oncology Nursing: Beyond Standard Care
- Multidisciplinary Team
- Comprehensive Geriatric Assessment
- Patient and Family Education
- Patient and Family Advocate
- Nursing Research in Geriatric Oncology
- Conclusions
- References
- Exercise for Older Cancer Patients: Feasible and Helpful?
- Abstract
- Older Adults Are at Risk for Functional Decline after a Cancer Diagnosis
- Impact of Cancer Treatment on Physical Health and Well-Being
- Rationale for Exercise to Improve Physical Health and Well-Being
- Benefits of Exercise in Non-Cancer Elderly Populations
- Exercise for Cancer Survivors
- Exercise in Older Cancer Patients - Rationale Is Strong but Evidence Is Lacking
- Unique Challenges for Older Adults
- Conclusion
- References
- Aging and Cancer - Addressing a Nation's Challenge
- Abstract
- Health Policy in Oncogeriatrics in France
- Lessons from the Pilot Phase
- Requirement Specifications of an Oncogeriatric Coordination Unit for the Next 3 Years
- Geriatric Assessment
- Conclusion
- References
- Author Index
- Subject Index
- Cover
